May 2012 - Researcher of the Month - Andisheh Abedini, PhD

Andisheh Abedini, PhD Research Interests
Dr. Abedini is interested in the role of RAGE in diabetes and metabolic disorders. Her current research focuses on the molecular and cellular mechanisms of RAGE in human amyloidosis and type 2 diabetes; with an emphasis on the development of rationally designed inhibitors of RAGE-mediated toxicity. Dr. Abedini received her PhD from the State University of New York at Stony Brook where she trained in biophysics and peptide chemistry. She joined Professor Ann Marie Schmidt’s research team in 2009 after training at the Joslin Diabetes Center at Harvard Medical School and spending one year as a Visiting Fellow at the Child and Family Research Institute at the University of British Columbia.

Peer-Reviewed Publications:
1. Cao P, Tu LH, Abedini A, Levsh O, Akter R, Patsalo V, Schmidt AM, Raleigh DP., Sensitivity of Amyloid Formation by Human Islet Amyloid Polypeptide to Mutations at Residue 20. J Mol Biol. 2011 Dec 21. [Epub ahead of print]

2. Fanling Meng, Andisheh Abedini, Annette Plesner, C. Bruce Verchere and Daniel P. Raleigh. “The flavanol (-)-epigallocatechin 3-gallate inhibits amyloid formation by islet amyloid polypeptide, disaggregates amyloid fibrils, and protects cultured cells against IAPP-induced toxicity.” (2010) Biochemistry 49(37):8127-33.

3. Fanling Meng, Daniel P. Raleigh and Andisheh Abedini. “Combination of kinetically selected inhibitors in trans leads to highly effective inhibition of amyloid formation.” (2010) J. Am. Chem. Soc. 132(41):14340-2.

4. Fanling Meng, Andisheh Abedini, Annette Plesner, C. T. Middleton, Katherine J. Potter, Martin T. Zanni, C. Bruce Verchere and Daniel P. Raleigh. “The sulfated triphenyl methane derivative acid fuchsin is a potent inhibitor of amyloid formation by human islet amyloid polypeptide and protects against the toxic effects of amyloid formation.” (2010) J. Mol. Biol. 400(3):555-66.

5. Kate Potter*, Andisheh Abedini*, Peter Merek, Miles Driscoll, Bruce Verchere and Daniel P. Raleigh. “Islet amyloid deposition limits the viability of human islet grafts but not porcine islet cell grants” (2010) PNAS, 107(9), 4305–4310. 

6. Ping Cao, Fanling Meng, Andisheh Abedini and Daniel P. Raleigh. “The ability of rodent islet amyloid polypeptide to inhibit amyloid formation by human islet amyloid polypeptide has important implications for the mechanism of amyloid formation and the design of inhibitors.” (2010) Biochemistry, 49(5):872-81.

7. Andisheh Abedini and Daniel P. Raleigh. “A critical assessment of the role of helical Intermediates in amyloid fibril formation” (2009) Protein Engineering, Design and Selection, 22(8):453-9.

8. Andisheh Abedini and Daniel P. Raleigh. “A role for helical intermediates in amyloid formation by
natively unfolded polypeptides" (2009) Physical Biology, 6(1) article ID15005.

9. Andisheh Abedini and Daniel P. Raleigh. "Protein Misfolding: Amyloid Formation." (2008) Wiley Encyclopedia of Chemical Biology. John Wiley and Sons.

10. Andisheh Abedini, Fanling Meng and Daniel P. Raleigh. “A single point mutation converts highly amyloidogenic human islet amyloid polypeptide into a potent inhibitor of fibrillization.” (2007) Journal of the American Chemical Society, 129(37) 11300-11301.

11. Fanling Meng, Andisheh Abedini, Benben Song and Daniel P. Raleigh. “Amyloid formation by proIAPP processing intermediates: Examination of the role of protein-heparan sulfate interactions and implications for islet amyloid formation in type 2 diabetes.” (2007) Biochemistry, 46(43)12091-12099.

12. Peter Marek, Andisheh Abedini, Ben Ben Song, Mandakini Kanungo, Megan E. Johnson,  Ruchi Gupta, Warda Zaman, Stanislaus S. Wong and Daniel P. Raleigh. “Aromatic interactions are not required for amyloid formation by islet amyloid polypeptide but do influence the rate of fibril formation and fibril morphology.” (2007) Biochemistry, 46(11) 3255-3261.

13. Andisheh Abedini*, Sylvia M. Tracz*, Jae-Hyun Cho and Daniel P. Raleigh. “Characterization of the heparin binding site in the N-terminus of human pro-islet amyloid polypeptide: Implications for amyloid formation.” (2006) Biochemistry 45(30), 9228-9237.

14. Andisheh Abedini, Gagandeep Singh and Daniel P. Raleigh. “Recovery and purification of highly aggregation-prone disulfide-containing peptides: Application to islet amyloid polypeptide.” (2006) Analytical Biochemistry 351, 181-186.

15. Andisheh Abedini and Daniel P. Raleigh. “Destabilization of human IAPP amyloid fibrils by proline mutations outside of the putative amyloidogenic domain: Is there a critical amyloidogenic domain in human IAPP?” (2006) Journal of Molecular Biology 355(2), 274-281.

16. Andisheh Abedini and Daniel P. Raleigh. “The role of His-18 in amyloid formation by human islet amyloid polypeptide.” (2005) Biochemistry, 44(49), 16284-16291.

17. Andisheh Abedini and Daniel P. Raleigh. “Incorporation of pseudoproline derivatives allows the facile synthesis of human IAPP; a highly amyloidogenic and aggregation-prone polypeptide.” (2005) Organic Letters 7, 693-696.

18. Sylvia M. Tracz*, Andisheh Abedini*, Miles Driscoll and Daniel P. Raleigh. “The role of aromatic interactions in amyloid formation by polypeptides: Analysis of peptides derived from human amylin.” (2004) Biochemistry 43, 15901-15908. 

*Joint first authors

Invited Book Chapters and Reviews:
1. Andisheh Abedini and Daniel P. Raleigh. “Islet Amyloid Polypeptide.” (2009) In: Protein Misfolding Diseases: Current and Emerging Principles and Therapies. Edited by Christopher M. Dobson, Jeffery W. Kelly and Marina Ramirez-Alvarado. Published by John Wiley and Sons.

2. Andisheh Abedini, Ruchi Gupta, Peter Marek, Fanling Meng, Daniel P. Raleigh and Sylvia Tracz and Taskent H. “Post Translational Modifications and Amyloid Formation.” (2009) In: Protein Misfolding Diseases: Current and Emerging Principles and Therapies. Edited by Christopher M. Dobson, Jeffery W. Kelly and Marina Ramirez-Alvarado. Published by John Wiley and Sons.

3. Andisheh Abedini and Steven E. Shoelson. “STAMPing out insulin resistance?” (2007) Immunology and Cell Biology, 85(6): 399-400. 

Conference Abstracts and Invited Talks:
“RAGE is a molecular mechanism of islet amyloid induced cell death” (2012) FASEB: The Protein Society Conference, San Diego, CA, USA.

“Chemical biology of islet amyloidosis points to RAGE as a cellular mechanism of islet Amyloidosis” (2012) The Chemical Biology Discussion Group Year End Symposium of the New York Academy Of Sciences, 7 World Trade Center,  New York, NY, USA.

“RAGE and islet amyloidosis: A mechanism of cellular toxicity in T2D” (2011) FASEB: Basic Origins and Medical Consequences of Protein Aggregation, Snowmass, CO, USA.

“RAGE and toxic intermediates during IAPP amyloid formation” (2011) The New York Structural Biology Discussion Group 6th Winter Meeting of the New York Academy Of Sciences, 7 World Trade Center,  New York, NY, USA.

“Mechanism of amyloid formation by IAPP and design of inhibitors of its toxicity and fibrillization” (2009) Department of Pathology, Child and Family Research Institute, University of British Columbia, Vancouver, B.C, Canada.

“From insulin resistance to type 2 diabetes: A biological and biophysical perspective” (2008) Biochemistry, Structural Biology and Chemistry Section, The Rockefeller University, New York, NY, USA.

“Adipose tissue macrophages and pathological inflammation in obesity-induced insulin resistance” (2008) Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany.

“Mechanistic and structural insight into amyloid formation by islet amyloid polypeptide: Implications for type 2 diabetes” (2006) Diabetes and Metabolism Research Unit, Boston Medical Center, Boston, MA, USA.

“Amyloid formation by human islet amyloid polypeptide” (2006) The Keystone Symposium on Protein Misfolding Diseases: Mechanisms of Misfolding, Pathology and Therapeutic Strategies, Breckenridge, CO, USA.

“The role of His-18 in amyloid assembly and morphology of human islet amyloid polypeptide” (2005) The 19th Symposium of the Protein Society, Boston, MA, USA.

“The role of His-18 in amyloid assembly and morphology of human islet amyloid polypeptide” (2005) The US-Japan Symposium on Protein Folding, Design and Dynamics, Philadelphia, PA, USA.

“Insight into the amyloidogenicity of human islet amyloid polypeptide” (2004) Protein Misfolding, Amyloid and Conformational Disease, Snowmass, CO, USA.

“Insight into the amyloidogenicity of human islet amyloid polypeptide” (2004) The 18th Symposium of the Protein Society, San Diego, CA, USA.

“CID assessment of doctoral programs: Northeastern, Stony Brook, Colorado and Ohio State” (2004) The 228th National Meeting of the American Chemical Society, Philadelphia, PA, USA.

“Formation and decomposition of 2-(2-phenylethyl)-imidazoline” (2001) 221st American Chemical Society, San Diego, CA, USA.

Future Plans:
Dr. Abedini is interested to continue contributing to our molecular and cellular level understanding of the role of RAGE in diabetes and metabolic disorders.